US Patent 11,357,820 (Tirzepatide Formulation) Claim Scope, Coverage Map, and Expiry/Challenge Risk
US Patent 11,357,820 is a tirzepatide injectable formulation patent centered on a narrow but practically important buffering and tonicity recipe: NaCl at defined mg/mL ranges, dibasic sodium phosphate at defined mg/mL ranges, optional preservatives (metacresol and/or phenol), defined pH, and downstream use and method-of-administration claims (including once-weekly dosing and automatic injection apparatus).
Core claim theme: protection is strongest against competitors making same concentration windows of tirzepatide plus specific excipient concentrations (NaCl and dibasic sodium phosphate), with secondary protection for preservative packages and pH.
What does US Patent 11,357,820 claim protect for tirzepatide injections?
Immediate answer: The patent protects a pharmaceutical composition containing tirzepatide (or salt) plus NaCl and dibasic sodium phosphate in specified concentration ranges, with optional metacresol/phenol preservatives, pH 6.5–7.5, and tied treatment/use and administration method claims.
Claim 1 is the anchor: excipient concentrations define the protected formulation
Claim 1 (independent):
- Tirzepatide (or pharmaceutically acceptable salt)
- NaCl: 6.2 mg/mL to 9.5 mg/mL
- Dibasic sodium phosphate (no explicit mg/mL stated in Claim 1 excerpt, but dependent claims narrow it)
This means any competing product that lands outside both excipient windows (especially NaCl) can avoid Claim 1 coverage.
Claim 2–4 tighten dibasic sodium phosphate
- Claim 2: tirzepatide concentration 5 to 30 mg/mL
- Claim 3: dibasic sodium phosphate 1 mg/mL to 3 mg/mL
- Claim 4: dibasic sodium phosphate 0.67 mg/mL to 2.68 mg/mL
- Claim 5: dibasic sodium phosphate about 1.34 mg/mL
Claims 6–11 lock in discrete tirzepatide concentrations and combined “sweet spot”
- Claim 6: tirzepatide concentration selected from 5, 10, 15, 20, 25, 30 mg/mL
- Claim 7: subset: 10, 20, 30 mg/mL
- Claim 8: NaCl about 7 mg/mL to about 9 mg/mL
- Claim 9: NaCl about 8.2 mg/mL
- Claim 10: combined ranges:
- tirzepatide 5–30 mg/mL
- dibasic sodium phosphate 0.67–2.68 mg/mL
- NaCl 6.2–9.5 mg/mL
- Claim 11: combined specific:
- tirzepatide 5–30 mg/mL
- dibasic sodium phosphate about 1.34 mg/mL
- NaCl about 8.2 mg/mL
Claim 12–13 define pH
- Claim 12: pH 6.5 to 7.5
- Claim 13: pH 6.7 to 7.3
Claims 14–23 define preservative options and concentrations
- Claim 14: composition further comprising one or more preservatives
- Claim 15: at least one of metacresol and phenol
- Claim 16: metacresol
- Claim 17: metacresol 2 to 4 mg/mL
- Claim 18: metacresol about 3.15 mg/mL
- Claim 19: phenol
- Claim 20: phenol 3 to 7 mg/mL
- Claim 21: phenol about 5 mg/mL
- Claim 22: metacresol 2 to 4 mg/mL with the core excipient recipe
- Claim 23: phenol 3 to 7 mg/mL with the core excipient recipe
Claims 24–25 define dosage volume and device compatibility
- Claim 24: dose volume about 0.5 mL
- Claim 25: suitable for administration using an automatic injection apparatus
Claims 26–27 are use claims tied to indications
- Claim 26: treatment of diabetes
- Claim 27: treatment of obesity
Claims 28–31 add a NaCl narrow band
- Claim 28: NaCl about 8.2 mg/mL to about 8.8 mg/mL
- Claim 29: NaCl 8.8 mg/mL
- Claim 31: dibasic sodium phosphate about 1.34 mg/mL where NaCl is 8.8 mg/mL
Claim 30 is a “full stack” composition
Claim 30: tirzepatide (5, 10, 15, 20, 25, 30 mg/mL) + NaCl 8.2 mg/mL + dibasic sodium phosphate 0.67–2.68 mg/mL + pH 6.5–7.5.
What are the independent method-of-use and administration claims in US 11,357,820?
Independent use claims are downstream and explicitly tethered to the composition claims.
Claim 32–34: diabetes + device + once-weekly
- Claim 32: method of treating diabetes by administering an effective dose of the composition of Claim 23
- Claim 33: dose administered using an automatic injection apparatus
- Claim 34: dose administered once weekly
Claim 35–37: obesity + device + once-weekly
- Claim 35: method of treating obesity by administering an effective dose of the composition of Claim 23
- Claim 36: device: automatic injection apparatus
- Claim 37: once weekly
Scope effect: If a competitor avoids Claim 23’s excipient-preservative package, it generally avoids these method claims as written.
How broad is Claim 1 vs the narrower dependent claims?
Featured-snippet style takeaway:
- Claim 1 is broad on NaCl (6.2–9.5 mg/mL) but only partial on dibasic sodium phosphate as provided in your excerpt.
- Dependent claims narrow by dibasic sodium phosphate, tirzepatide mg/mL, NaCl point values/bands, pH, preservatives, and volume.
Breadth ranking by excipient strictness (most to least constrained)
- Most constrained: compositions specifying exact combinations like NaCl 8.2 mg/mL + dibasic sodium phosphate ~1.34 mg/mL + pH 6.7–7.3, plus preservative and device/volume limitations (Claims 11, 30, 24–25, 22–23).
- Mid constrained: ranges with multiple excipient parameters together (Claim 10; Claim 22–23; Claim 12–13).
- Least constrained: Claim 1 and Claim 2 in isolation, because only NaCl is tightly defined while tirzepatide range is broad (Claim 2).
Practical consequence for formulation design-arounds
The patent’s strongest “knockout” lever for a challenger is excipients, not tirzepatide itself:
- Shift NaCl outside 6.2–9.5 mg/mL or avoid the specific bands like 8.2 mg/mL and 8.2–8.8 mg/mL.
- Shift dibasic sodium phosphate outside 0.67–2.68 mg/mL (or outside ~1.34 mg/mL if aiming for Claim 11/31).
- Shift pH outside 6.5–7.5 (or 6.7–7.3).
- Avoid the disclosed preservative package levels if Claim 22/23 is targeted.
What formulation variants create highest infringement risk under US 11,357,820?
Highest risk “squarely within” combinations
The excerpt contains multiple “target configurations” that are commercially typical formulation setpoints. These include:
- NaCl: ~8.2 mg/mL (Claim 9; Claim 11; Claim 30)
- Dibasic sodium phosphate: ~1.34 mg/mL (Claim 5; Claim 11; Claim 31)
- pH: 6.5–7.5 (Claim 12) and 6.7–7.3 (Claim 13)
- Preservatives:
- Metacresol: about 3.15 mg/mL (Claim 18), with metacresol 2–4 mg/mL (Claim 17; Claim 22)
- Phenol: about 5 mg/mL (Claim 21), with phenol 3–7 mg/mL (Claim 20; Claim 23)
- Dose volume: about 0.5 mL (Claim 24)
- Device: automatic injection apparatus (Claim 25; method claims 33, 36)
Why these are high risk
Because several dependent claims stack the same parameter values into a single compliant formulation. If a competitor’s product hits any one strong “combination claim” set, exposure rises quickly even if it misses other dependent claims.
What generic entry risks exist for tirzepatide products tied to this patent?
In-scope “generic” risk profile
For small-molecule injectable biologic analogs like tirzepatide (a peptide), competition generally comes via:
- biosimilar-style pathways are not applicable in the same way as antibodies because tirzepatide is a peptide drug, but copycat products still must match formulation and stability requirements.
- Practical generic/bioequivalent manufacturers still face formulation-IP barriers where the claims are explicitly excipient-composition based.
Under this patent’s structure, a generic entrant that:
- uses tirzepatide at a similar concentration,
- and reproduces the same NaCl + phosphate + pH window,
- and uses the same preservative system at disclosed levels,
is positioned for direct infringement risk.
Device and dosing language raises the bar
Even if excipient composition is aligned, method claims require:
- automatic injection apparatus
- and once weekly dosing
for both diabetes and obesity methods.
A challenger could reduce method-claim risk by changing:
- dosing regimen language, or
- device form factor (practically, this is harder once commercial labeling and user interface are standardized).
How does US 11,357,820 compare with typical tirzepatide patent themes?
Composition excipient IP vs peptide molecule IP
This patent is not about the peptide sequence. It focuses on:
- buffer system selection and concentration (dibasic sodium phosphate range and specific ~1.34 mg/mL)
- tonicity control (NaCl range and specific 8.2 mg/mL band)
- preservative system (metacresol and/or phenol with specified mg/mL targets)
- pH window
That pattern is consistent with formulation patents that survive molecule-expiry-based generic pressure longer than sequence or general manufacturing claims.
What patents likely sit adjacent to US 11,357,820 in the same estate?
Without the patent family dataset (publication numbers, continuations, related assignments, and earlier/later formulation patents), an adjacent landscape can be mapped only from claim logic:
- Expect co-pending or related patents covering:
- tirzepatide salt forms (pharmaceutically acceptable salts)
- alternative buffer systems or phosphate concentrations
- alternative preservative combinations
- pH adjustment and stability-optimized ranges
- container closure and automatic injection compatibility
- dosing volume optimization (about 0.5 mL)
This patent likely represents one formulation “slice” within a broader formulation estate.
What is the Orange Book status of US 11,357,820?
No complete and accurate Orange Book mapping can be produced from the information provided. Without a listing identifier (application/NDA/BLA, Orange Book patent code, expiration dates, and patent linkage), a reliable Orange Book status answer cannot be generated.
When does US 11,357,820 lose exclusivity?
No complete and accurate exclusivity timeline can be produced from the information provided. Patent expiration depends on:
- filing date / priority chain,
- maintenance and term adjustments,
- any pediatric extension,
- and the drug’s regulatory exclusivity timeline.
What patent litigation affects US 11,357,820?
No complete and accurate litigation status can be produced from the information provided. Litigation requires docket-based evidence tied to the specific patent number, including case captions, Paragraph IV/IXA filings (if any), and settlement agreements.
Key Claim Scope Table (parameter-by-parameter)
| Parameter |
Claim anchors in US 11,357,820 (from excerpt) |
Numeric windows / singled values |
| Tirzepatide concentration |
Claims 2, 6, 10, 11, 30 |
5–30 mg/mL; specific set: 5/10/15/20/25/30 mg/mL; subset 10/20/30 |
| NaCl |
Claims 1, 8, 9, 10, 11, 28, 29, 30 |
6.2–9.5 mg/mL; 7–9 mg/mL; about 8.2 mg/mL; 8.2–8.8 mg/mL; 8.8 mg/mL; combo 10 and 11 |
| Dibasic sodium phosphate |
Claims 3–5, 4, 10–11, 30, 31 |
1–3 mg/mL; 0.67–2.68 mg/mL; about 1.34 mg/mL |
| pH |
Claims 12–13 |
6.5–7.5; 6.7–7.3 |
| Preservatives |
Claims 14–23 |
metacresol (2–4 mg/mL; about 3.15 mg/mL), phenol (3–7 mg/mL; about 5 mg/mL), either or both via dependent stacking |
| Dose volume |
Claim 24 |
about 0.5 mL |
| Automatic injection apparatus |
Claims 25, 33, 36 |
device-compatibility limitation in composition and methods |
| Indication |
Claims 26–27, 32, 35 |
diabetes, obesity |
| Dosing frequency |
Claims 34, 37 |
once weekly |
How should competitors design around this patent’s claim structure?
Best-performing design-around levers are compositional:
- Move NaCl outside the broad window 6.2–9.5 mg/mL to avoid Claim 1, or outside the specific risk points/bands like about 8.2 mg/mL and 8.2–8.8 mg/mL.
- Move dibasic sodium phosphate outside 0.67–2.68 mg/mL (or away from ~1.34 mg/mL) to avoid Claim 4/5/10/11/30/31.
- Move pH outside 6.5–7.5 (or 6.7–7.3) to defeat Claim 12/13 stack.
- Change the preservative system and/or its mg/mL concentration to avoid Claim 22/23 stacking.
Device and once-weekly limitations in method claims are secondary barriers. If a competitor uses a different regimen or device architecture, method-claim exposure may drop, but composition infringement remains the primary risk driver.
Key Takeaways
- US 11,357,820 is an injectable tirzepatide formulation patent with claim coverage driven by excipient concentrations: NaCl (6.2–9.5 mg/mL; plus specific bands and values like ~8.2 mg/mL and 8.8 mg/mL) and dibasic sodium phosphate (0.67–2.68 mg/mL and ~1.34 mg/mL).
- Claim scope expands through stacking parameters: tirzepatide 5–30 mg/mL, pH 6.5–7.5 (or 6.7–7.3), and optional metacresol (2–4 mg/mL; ~3.15 mg/mL) and/or phenol (3–7 mg/mL; ~5 mg/mL).
- Downstream method-of-use claims add automatic injection apparatus and once-weekly dosing for diabetes and obesity, but they are tethered to composition claims (notably Claim 23 in the method claim text you provided).
- The highest infringement exposure comes from formulations that match the “combo” targets (notably NaCl ~8.2 mg/mL + dibasic sodium phosphate ~1.34 mg/mL + pH 6.5–7.5, with the relevant preservative system).
FAQs
1) Which excipient parameter is the most effective trigger to avoid Claim 1 of US 11,357,820?
NaCl, because Claim 1’s independent boundary is NaCl at 6.2–9.5 mg/mL.
2) Do the preservative claims require both metacresol and phenol?
No. The patent allows compositions with one or more preservatives and specifies either metacresol or phenol through dependent claims.
3) What pH range would most directly avoid the pH-dependent claims?
Avoid pH 6.5–7.5 (and specifically 6.7–7.3).
4) Can a once-weekly dosing change eliminate method-claim risk?
The method claims explicitly require once weekly in claims 34 and 37, so changing dosing frequency and related labeled/used regimen can reduce method-claim exposure, while composition infringement still depends on the formulation parameters.
5) Does the patent restrict container volume or only composition chemistry?
It includes a volume limitation in Claim 24 (about 0.5 mL) and a device limitation via automatic injection apparatus in Claim 25 and method claims.
References
- US Patent No. 11,357,820. Claims provided in user prompt (tirzepatide composition comprising NaCl, dibasic sodium phosphate, optional metacresol/phenol, pH limits, and method-of-use for diabetes/obesity with automatic injection and once-weekly dosing).
